Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
The UNIVERSITY OF GREENWICH maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. There are 2 pending office actions currently active. These actions are spread across 2 distinct examiners and 2 distinct art units. This distribution shows diversity in the portfolio's current prosecution landscape. The presence of 2 distinct examiners suggests that the university is pursuing different technical threads simultaneously. The 2 pending office actions represent the current active workload for the university's intellectual property team.
CHANDRAKUMAR, NIZAL S is the busiest examiner, with 1 pending office action. This examiner handles a portion of the total pending actions for the portfolio. Because there are 2 distinct examiners and 2 distinct art units, practitioners must adapt their strategies to different sets of examiner preferences and art unit standards. This variety requires a flexible approach. Coordination across the 2 distinct art units may be necessary to ensure consistent prosecution outcomes for the UNIVERSITY OF GREENWICH. This diverse workload requires the practitioner to monitor multiple procedural tracks simultaneously.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.3% |
| FIEBIG, RUSSELL G | 1 | 62.6% | +25.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17921030 | DIAZINE AND TRIAZINE COMPOUNDS TO TREAT CYTOKINE STORM SYNDROME | CHANDRAKUMAR, NIZAL S | 142d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17921030 | DIAZINE AND TRIAZINE COMPOUNDS TO TREAT CYTOKINE STORM SYNDROME | CHANDRAKUMAR, NIZAL S | 142d overdue |
| 17964312 | PRODUCTION OF DUNALIELLA | FIEBIG, RUSSELL G | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17921030 | DIAZINE AND TRIAZINE COMPOUNDS TO TREAT CYTOKINE STORM SYNDROME | CHANDRAKUMAR, NIZAL S | 1625 | §103§112Other | Final Rejection | 142d overdue | Pending | Oct 24, 2022 |
| 17964312 | PRODUCTION OF DUNALIELLA | FIEBIG, RUSSELL G | 1655 | §103 | Non-Final OA | — | Pending | Oct 12, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial